Transplantation of human hematopoietic stem cell (HSC) containing grafts has emerged as a standard therapy to cure several diseases, especially leukemia. In 2014, a record number of 40 829 HSC transplantations (HSCTs) were performed in Europe, out of which 42% were allogeneic. 1 Conventionally, the total nucleated cell count (TNC) and the content of CD34 + cells are used as quality control criteria for HSC grafts. 2, 3 Some groups consider TNC to be a better predictor of HSCT outcomes than the number of transplanted CD34 + cells. 4 This might be related to the heterogeneity of the CD34 + cell fraction. Although human HSCs are included in the CD34 + cell fraction, this population contains a mixture of different hematopoietic stem and progenitor cells (HSPCs). Novel cell surface marker combinations now allow for the dissection of CD34 + populations into different HSPC types either being multipotent or committed to the lymphomyeloid or erythromyeloid lineages. [5] [6] [7] [8] [9] Although the analysis of CD34 + subpopulations has massively increased our understanding in early human hematopoiesis, such subpopulation analyses have only been reported for HSCT grafts, but not for the reconstituted bone marrow (BM) following HSCT.
5,7,10-12
Now, Dmytrus et al. 13 have comprehensively analyzed HSPC subpopulations in grafts before and in the BM of patients 1 year after HSCT. Interestingly, in comparison with the original grafts, the authors observed a significant decrease in more primitive and an increase in more mature HSPC frequencies after HSCT. Here we summarize and discuss these findings in a broader context. Today, different human HSPC subsets can be identified by analyzing the expression profiles of different cell surface Ags, mainly of CD34, CD133, CD45RA, CD38 and CD10. Of note and as previously discussed in detail, especially the inclusion of the cell surface marker CD133 resulted in the identification of unexpected lineage relationships, which were incompatible with prevailing models of human hematopoiesis, and let us propose a revised model of hematopoiesis ( Figure 1) . 6, 14, 16 Now, by using a multicolor flow-cytometric panel comprising Abs against all these Ags, Dmytrus et al. 13 performed immunephenotypic analyses of both HSC grafts before and the BM of patients 1 year after HSCT. By applying this panel, the authors were able to detect defined subsets of HSPCs, and compared their content and frequencies between PBSC and BM grafts, and between graft and patient BM samples after HSCT. The authors detected differences in the HSPC composition between PBSC and BM grafts being similar to the previous studies; CD34 + cells in PBSC samples contained significantly higher HSC/MPP frequencies than those in BM samples. 5 However, the authors demonstrate unexpected huge differences regarding the composition of CD34 + cell fractions within BM samples before and following HSCT. They observed a two to threefold decreased content of total CD34 + cells in patient's BM 1 year after receiving HSCT compared with the transplanted donor BM. Even more strikingly, the authors detected a reproducible shift from HSCs/MPPs towards more mature HSPC subtypes. The absolute number of HSCs/MPPs in a given volume of BM was reduced in the patients after HSCT (427 fold). In addition, the authors recorded a reduction in LMPP and EMP frequencies; in contrast, late lymphomyeloid progenitor frequencies (MLPs and CD19 + B cell progenitors) were massively increased. Thus, the authors documented a clear shift from more primitive to more mature HSPC types, which might affect the efficacy of hematopoiesis in patients short and/or long-term.
This observed shift within the HSPC pool could be explained by different scenarios. One possible explanation might be that the capacity of HSCs/MPPs to self-renew could be limited in general. Notably, in vitro, MPPs were found to mainly divide asymmetrically to create a pair of CD133 + and CD133 − daughter cells, revealing LMPP or EMP potentials, respectively. 15 So far, we considered that the in vitro conditions used severely affect the division mode of MPPs, and have started to study MPP dynamics under different culture conditions. In this context, we recently showed that cocultivation with mesenchymal stem/stromal cells (MSCs) does not support HSC/MPP expansion or even their maintenance, but promotes the development of lymphomyeloid progenitors. from our in vitro studies and the novel data of Dmytrus et al., 13 it is tempting to hypothesize that MPPs in principle cannot self-renew, and irrespective of the environmental conditions divide asymmetrically to create LMPPs and EMPs. Alternatively, HSC/MPP-supporting niches might have been damaged in the patients before or following HSCT, and thus have lost their capability to efficiently support HSC/MPP expansion at least within the first year following HSCT.
Another possible explanation might be that the expansion of HSCs/MPPs might be too slow to establish a normal steady-state BM in patients within the first year after HSCT. Because of the limited number of transplanted HSCs/MPPs, it appears unlikely that all available HSC/MPP-niches become occupied immediately after HSCT. It might take more time until enough HSCs/MPPs are produced to fill all niches available. Long-term follow-up analyses of the HSPC composition in HSCT patients surely will reveal important new knowledge about human hematopoiesis and help to get a clearer picture about the observed shift.
If it comes to BM analyses in patients following HSCT, a very recent study analyzed the CD34 and CD133 expression in BM and peripheral blood of 27 patients after transplantation, and observed normal CD34 + /CD133 + ranges at median 155 days post-HSCT. 18 However, as CD45RA expression was not analyzed, multipotent and lymphomyeloid HSPCs cannot be discriminated. Consequently, a shift from more primitive to more mature HSPC subsets could not have been identified. For analyses of HSC grafts and BM samples from HSCT patients, we recommend to study at least the expression of CD133 and CD45RA together with that of CD34. These three markers are crucial to comprehensively discriminate different HSPC subsets (Figure 1) .
In summary, Dmytrus et al. 13 provide a first comprehensive and multiparameter phenotypic comparison of HSPC subsets before and after HSCT. Their results provide important new aspects for HSCT. Related to the clinical situation, a number of novel aspects can be addressed: the HSPC composition in the grafts was compared with the situation in the BM 1 year after HSCT. 13 Although it will be ethically challenging, BM analyses at regular intervals might help to unravel HSPC repopulation dynamics following HSCT, and avoid a potential 'single time point bias'. The majority of patients whose BM was examined after allogeneic HSCT had received antithymocyte globulins (ATG) (15/21). In this context, it would be of high interest to perform subgroup analyses of ATG-vs non-ATG-treated patients, and if ethically possible compare the HSPC composition at different time points following HSCT (e.g., 3, 6 and 12 months). Furthermore, correlation of results from HSPC subset analyses with clinical data might address and answer a number of important questions: Is there a relationship between HSPC composition and engraftment, GvHD, infection burden, chimerism or relapse? Of note, the median age of patients in the study of Dmytrus et al. 13 was 10 years. Even though we may not expect huge differences in adult HSCT patients, it should be tested whether a comparable scenario is found in adult patients following HSCT.
Up to now, BM examinations following HSCT have been primarily performed routinely to evaluate the remission status of the given patient and to detect minimal residual disease in an early stage. The work of Dmytrus et al. 13 might help to reconsider the monitoring procedure of patients following HSCT to also gain important information about the reconstitution dynamics in patients following HSCT. 
